Anúncio
Anúncio
CHRS
Coherus Oncology, Inc. Common Stock
1.70
USDPatrocinado
+0.17
+10.78%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
1.72
+0.02
+1.18%
Relatórios de Lucros CHRS
Rácio de surpresa positiva
CHRS separação 15 de 40 últimas estimativas.
38%
Próximo Relatório
Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$14.48M
/-$0.35
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+25.12%
/+6.06%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-73.26%
/+25.00%
Coherus Oncology, Inc. Common Stock earnings per share and revenue
On 06 de nov. de 2025, CHRS reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.33 USD, resulting in a 0.45% surprise. Revenue reached 11.57 milhão, compared to an expected 13.68 milhão, with a -15.43% difference. The market reacted with a -10.07% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of -0.35 USD, with revenue projected to reach 14.48 milhão USD, implying an aumentar of 6.06% EPS, and aumentar of 25.12% in Revenue from the last quarter.
FAQ
What were Coherus Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Coherus Oncology, Inc. Common Stock reported EPS of -$0.33, missing estimates by 0.45%, and revenue of $11.57M, -15.43% below expectations.
How did the market react to Coherus Oncology, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -10.07%, changed from $1.49 before the earnings release to $1.34 the day after.
When is Coherus Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 de mar. de 2026.
What are the forecasts for Coherus Oncology, Inc. Common Stock's next earnings report?
Based on 7
analistas, Coherus Oncology, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of $14.48M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio